Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

BMC Veterinary Research

Volumn 9, Issue , 2013, Pages

  Bernabe, Luis F ^a   Portela, Roberta ^b   Nguyen, Sandra ^a   Kisseberth, William C ^a   Pennell, Michael ^a   Yancey, Mark F ^c   London, Cheryl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c ZOETIS   (United States)

Author keywords

Cancer; Dog; Toceranib phosphate; VEGF

Indexed keywords

CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TOCERANIB; VASCULOTROPIN A;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INDOLES; MALE; NEOPLASMS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884696777     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-9-190     Document Type: Article

References (21)

1. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 15(11):3856-3865. 10.1158/1078-0432.CCR-08-1860, 19470739.
2. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100(2):585-593. 10.1182/blood-2001-12-0350, 12091352.
3. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003, 9(7):2755-2768.
4. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
5. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003, 9(15):5729-5734.
6. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia) in solid tumours. Vet Comp Oncol 2012, 10(3):194-205. 10.1111/j.1476-5829.2011.00275.x, 3732378, 22236194.
7. Yancey MF, Merritt DA, Lesman SP, Boucher JF, Michels GM. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther 2010, 33(2):162-171. 10.1111/j.1365-2885.2009.01133.x, 20444041.
8. Yancey MF, Merritt DA, White JA, Marsh SA, Locuson CW. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. J Vet Pharmacol Ther 2010, 33(2):154-161. 10.1111/j.1365-2885.2009.01120.x, 20444040.
9. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011, doi:10.1111/j.1476-5829.2011.00283.x [Epub ahead of print].
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
11. Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2012, 13(9):1323-1336. 10.1517/14656566.2012.689130, 22607009.
12. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48(1):9-17. 10.1080/02841860802314720, 18752081.
13. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, Firvida-Perez JL, Vazquez-Estevez S, Lazaro-Quintela M, Ramos-Vazquez M, Fernandez-Calvo O, Campos-Balea B, Anton-Aparicio LM. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011, 22(1):1-8. 10.1097/CAD.0b013e3283403806, 20938340.
14. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 2013, 31(3):444-454. 10.1097/HJH.0b013e32835c1d1b, 23221987.
15. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103(9):763-773. 10.1093/jnci/djr128, 3086879, 21527770.
16. Pallotti MC, Pantaleo MA, Nannini M, Centofanti F, Fabbrizio B, Montanari M, Baraldi O, Saponara M, Lolli C, Mandrioli A, et al. Development of a nephrotic syndrome in a patient with gastrointestinal stromal tumor during a long-time treatment with sunitinib. Case Rep Oncol 2012, 5(3):651-656. 10.1159/000345946, 3531949, 23275781.
17. Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Ann Pharmacother 2012, 46(10):e27. 10.1345/aph.1R160, 23032654.
18. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, Wesseling S, Strevens H, Jan Danser AH, van den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011, 58(2):295-302. 10.1161/HYPERTENSIONAHA.111.173559, 21670421.
19. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008, 100(4):282-284. 10.1093/jnci/djm311, 18270341.
20. Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009, 12(1):69-79. 10.1007/s10456-009-9133-9, 19212818.
21. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104(43):17069-17074. 10.1073/pnas.0708148104, 2040401, 17942672.